---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-25-000001"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:01:36.396854+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iBio licenses anti-myostatin antibody IBIO-600 from AstralBio; launches bispecific program for obesity

## Summary
- Upfront payment of $750,000 paid in common stock; milestones up to $28M.
- IBIO-600 is a long-acting anti-myostatin antibody designed for subcutaneous use.
- iBio initiated a bispecific antibody program targeting myostatin/activin A for obesity and cardiometabolic disorders.
- Preclinical studies show potent myostatin inhibition; NHP data expected early 2025.
- Plans to enter clinical trials in obesity and cardiometabolic disorders in 2026.

## SEC filing metadata
- accession: 0001420720-25-000001
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/0001420720-25-000001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/ibio-20241230x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-25-000001
- JSON: https://secwatch.observer/filing/0001420720-25-000001.json
- Plain text: https://secwatch.observer/filing/0001420720-25-000001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.